Apogee CEO Michael Henderson at #JPM24 (Brian Benton Photography)
Apogee reports Phase 2 win for eczema drug that could challenge Dupixent and Ebglyss
Apogee Therapeutics said on Monday that its atopic dermatitis candidate, which has the potential to offer a more convenient alternative to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
